# Atorvastatin ± Aspirin in Lynch Syndrome Syndrome

> **NCT04379999** · EARLY_PHASE1 · COMPLETED · sponsor: **Fox Chase Cancer Center** · enrollment: 43 (actual)

## Conditions studied

- Lynch Syndrome

## Interventions

- **DRUG:** Atorvastatin 20mg
- **DRUG:** Atorvastatin 20mg AND Aspirin 325 mg

## Key facts

- **NCT ID:** NCT04379999
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-10
- **Primary completion:** 2025-08-04
- **Final completion:** 2025-08-04
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2025-08-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04379999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04379999, "Atorvastatin ± Aspirin in Lynch Syndrome Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04379999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*